Cervical Intraepithelial Neoplasia Clinical Trial
Official title:
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
This study was designed to enable all subjects who received placebo in the HPV-039 study (NCT00779766), to also receive GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed. Safety data in terms of serious adverse events (SAEs), any adverse events (AEs)/SAEs leading to premature discontinuation of the study, potential immune mediated diseases (pIMDs) and pregnancies (and their outcomes) were collected during the study period. In addition, this study assessed the long term protective effect of the vaccine, in an exploratory manner, in terms of rates of HPV-related (vaccine type) incident cervical infection up to approximately 10 years after vaccination in subjects who participated in HPV-039 study (NCT00779766).
Treatment allocation depended on the randomization in the previous study i.e. only the subjects from the control group of HPV-039 study received HPV vaccination in the current study. Subjects who previously received the Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed in HPV-039 study did not receive vaccination in this study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Completed |
NCT02907333 -
Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia
|
N/A | |
Recruiting |
NCT02576262 -
HPV Integration Testing for Human Papillomavirus-Positive Women
|
N/A | |
Completed |
NCT01029990 -
Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program
|
Phase 0 | |
Recruiting |
NCT05078528 -
Low-cost Imaging Technology for Global Prevention of Cervical Cancer
|
N/A | |
Recruiting |
NCT05502367 -
A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
|
Phase 1/Phase 2 | |
Completed |
NCT02494310 -
HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings
|
N/A | |
Active, not recruiting |
NCT03429582 -
Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device
|
N/A | |
Active, not recruiting |
NCT02140021 -
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
|
N/A | |
Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
Completed |
NCT02237326 -
Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women
|
N/A | |
Completed |
NCT00316706 -
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
|
Phase 3 | |
Withdrawn |
NCT03143491 -
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
|
Phase 2 | |
Completed |
NCT03293628 -
Comparing Two Techniques of Haemostasis After Cervical Conization
|
Phase 2 | |
Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT02481414 -
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
|
Phase 2 | |
Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
Recruiting |
NCT04650711 -
Immunohistochemical Staining of p16 for the Screening of Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT04646954 -
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
|
Phase 3 | |
Completed |
NCT01544478 -
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
|
Phase 4 |